Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker study of ocrelizumab in relapsing and primary progressive multiple sclerosis
2015-004616-37Phase 3Completed
- Sponsor
- Genentech
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS), sponsored by Genentech. Primary endpoint: Change in cerebrospinal fluid neurofilament light levels. Started Apr 2016; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on 2015-004616-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004616-37.